News
Omburtamab filed with MAA for pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.- Y-mAbs Therapeutics
Y-mAbs Therapeutics announced that the Company has submitted its Marketing Authorization Application to the European Medicines Agency for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. Y-mAbs recently concluded a Type B meeting with the FDA regarding omburtamab and the Company continues to be in close dialog with the FDA and maintains its aim of resubmitting the Biologics License Application to the FDA late in the second quarter or in the third quarter of 2021.
Condition: Neuroblastoma
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins